USE OF VENLAFAXINE IN THE TREATMENT OF AUTONOMIC DYSREGULATIONS WITH SYMPATHETIC DEFICIT

摘要

The present invention relates to medicine. It describes a novel use of Venlafaxine in the treatment of autonomic dysregulations with sympathetic deficit, more specifically symptomatic dysautonomic bradycardia subsequent either to substantial vagal hyperactivity, or to central or peripheral β sympathetic deficits. This molecule is also indicated in the presence of central and/or peripheral α sympathetic deficit responsible for arterial hypotension. The invention makes it possible to provide a novel pharmacological means for treating autonomic dysregulations with sympathetic deficit, with a beneficial effect of Venlafaxine. The novel use of the medicament has an action with a dose of 37.5 to 70 mg taken once a day orally, and thus increases sympathetic activity. The diagnosis of sympathetic deficit is made by means of sympathetic stimulation tests. The effect of the novel use is positive on the central and peripheral alpha and/or beta sympathetic nervous system, thus making it possible to increase AP (arterial pressure) and HR when the latter are abnormally low or when the sympathetic stimulation tests demonstrate a weak response.